Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Raf kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (65) Akt (5) Antibiotic (1) Apoptosis (12) Autophagy (15) Bacterial (1) Bcl-2 Family (2) Bcr-Abl (1) c-Kit (5) c-Met/HGFR (1) Cadherin (2) Caspase (1) Cathepsin (1) CDK (1) DNA/RNA Synthesis (1) EGFR (6) Ephrin Receptor (1) ERK (4) FGFR (7) FLT3 (2) G Protein-coupled Receptor Kinase (GRK) (1) GLUT (1) HSP (1) Isotope-Labeled Compounds (2) JNK (2) MAP3K (1) MDM-2/p53 (1) MEK (9) MMP (3) p38 MAPK (5) PARP (2) PDGFR (6) PI3K (4) Pim (1) Ras (3) Reference Standards (7) RET (7) Src (3) STAT (2) TAM Receptor (1) Tie (6) VEGFR (14)
By Research Areas:	Cancer (73) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (5)

By Targets:

Raf (65)

Akt (5)

Antibiotic (1)

Apoptosis (12)

Autophagy (15)

Bacterial (1)

Bcl-2 Family (2)

Bcr-Abl (1)

c-Kit (5)

c-Met/HGFR (1)

Cadherin (2)

Caspase (1)

Cathepsin (1)

CDK (1)

DNA/RNA Synthesis (1)

EGFR (6)

Ephrin Receptor (1)

ERK (4)

FGFR (7)

FLT3 (2)

G Protein-coupled Receptor Kinase (GRK) (1)

GLUT (1)

HSP (1)

Isotope-Labeled Compounds (2)

JNK (2)

MAP3K (1)

MDM-2/p53 (1)

MEK (9)

MMP (3)

p38 MAPK (5)

PARP (2)

PDGFR (6)

PI3K (4)

Pim (1)

Ras (3)

Reference Standards (7)

RET (7)

Src (3)

STAT (2)

TAM Receptor (1)

Tie (6)

VEGFR (14)

By Research Areas:

Cancer (73)

Cardiovascular Disease (2)

Infection (3)

Inflammation/Immunology (6)

Metabolic Disease (4)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10201

Sorafenib Maximum Cited Publications 283 Publications Verification Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and *RAF* family kinases, thereby suppressing the *RAF/MEK/ERK* and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

HY-10331

Regorafenib 85+ Cited Publications BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-12057

Vemurafenib 100+ Cited Publications PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-10320

Doramapimod 50+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits *B-Raf* with an IC₅₀ of 83 nM .

HY-15246

Tovorafenib 5+ Cited Publications TAK-580; MLN 2480; BIIB-024	Raf	Cancer
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of *pan-Raf* kinase. Tovorafenib can be used for the study of glioma .

HY-10966

SB-590885 5+ Cited Publications	Raf Apoptosis	Neurological Disease Metabolic Disease Cancer
SB-590885 is a *BRAF/c-Raf* kinase inhibitor that selectively targets *B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf* cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

HY-10201A

Sorafenib tosylate Maximum Cited Publications 283 Publications Verification Bay 43-9006 tosylate	Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and *RAF* family kinases, thereby suppressing the *RAF/MEK/ERK* and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

HY-14660A

Dabrafenib Mesylate 75+ Cited Publications GSK2118436 Mesylate; GSK 2118436B	Raf	Cancer
Dabrafenib Mesylate is a potent and selective **Raf kinase inhibitor with IC₅₀*s of 0.6 and 5.0 nM for Raf* ^V600E and c-Raf, respectively.

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-18832

AWL-II-38.3	Ephrin Receptor	Cancer
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf .

HY-112780

UC2288 5+ Cited Publications	MDM-2/p53 Apoptosis	Cancer
UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM .

HY-N6670

Cefotetan	Antibiotic Raf ERK Ras MEK Bacterial	Infection
Cefotetan is a binding agent that targets *human Raf1 kinase* inhibitor protein (hRKIP). Cefotetan binds to hRKIP, reduces the binding space between hRKIP and Raf1 kinase, relieves hRKIP's inhibition of the Ras/Raf1/MEK/ERK signaling pathway, and enhances ERK** phosphorylation. Cefotetan can be used to study diseases associated with dysregulated Ras/Raf1/MEK/ERK signaling pathways. Cefotetan is also a broad-spectrum antibacterial agent that disrupts cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). It is used to study bacterial infections such as bone, skin, urinary tract, and lower respiratory tract .

HY-18957

Lifirafenib 2 Publications Verification BGB-283	EGFR Raf	Cancer
Lifirafenib (BGB-283) is a novel and potent *Raf* Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively.

HY-10331A

Regorafenib monohydrate 85+ Cited Publications BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-11004

AZ 628 10+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a *pan-Raf* kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-11010

AS601245 5+ Cited Publications	JNK	Neurological Disease Inflammation/Immunology Cancer
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-13343

ZM 336372 2 Publications Verification	Raf Apoptosis	Cancer
ZM 336372 is a potent inhibitor of the protein kinase *c-Raf. The IC₅₀* value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.

HY-107779

BI-882370	Raf	Cancer
BI-882370 is a potent and selective *RAF* kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF ^V600E-mutant, the WT BRAF and CRAF kinases with IC₅₀s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .

HY-12787

L-779450 1 Publications Verification	Raf Autophagy	Cancer
L-779450 is a potent and selective *B-Raf* kinase inhibitor with a K_d of 2.4 nM.

HY-12291

HG6-64-1 HMSL 10017-101-1	Raf Apoptosis	Cancer
HG6-64-1 (HMSL 10017-101-1) is a *B-raf* kinase modulator.HG6-64-1 modulates *B-raf* kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-P1039A

R18 TFA PHCVPRDLSWLDLEANMCLP TFA	Raf	Cancer
R18 TFA is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-77113

B-Raf IN 11	Raf	Cancer
B-Raf IN 11 is a *B-Raf* ^V600E mutant kinase inhibitor with an IC₅₀ of 76 nM, and exhibits an IC₅₀ of 238 nM against wild-type *B-Raf* kinase. B-Raf IN 11 inhibits the kinase activities of *B-Raf* ^V600E mutant and wild-type *B-Raf* kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .

HY-18227

B-Raf IN 1	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

HY-109574

Raf inhibitor 2 1 Publications Verification	Raf	Cancer
Raf inhibitor 2 is a potent **raf kinase** (IC₅₀<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .

HY-W013411A

Locostatin 3 Publications Verification UIC-1005	Raf G Protein-coupled Receptor Kinase (GRK)	Cancer
Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-136567

TBAP-001	Raf	Cancer
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC₅₀ of 62 nM in BRAF V600E kinase assay .

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-159534

Flezurafenibum FlezuRafenib	Raf	Cancer
Flezurafenibum (Flezurafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, with antineoplastic effect .

HY-117658

GSK-114	MAP3K	Cardiovascular Disease
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC₅₀= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC₅₀= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a **RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀** values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Raf	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-159508

Brimarafenib	Raf	Cancer
Brimarafenib is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor wtih antineoplastic effect .

HY-147125

DDO-6600	HSP Akt CDK Raf Apoptosis	Cancer
DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, *c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis*. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer .

HY-14177A

Raf inhibitor 1 dihydrochloride 3 Publications Verification	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-W013411

(E/Z)-Locostatin (E/Z)-UIC-1005	Raf	Cancer
(E/Z)-Locostatin ((E/Z)-UIC-1005) is a racemic of Locostatin. Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-19343

XL-281 BMS-908662	Raf	Cancer
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC₅₀s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity .

HY-10331B

Regorafenib mesylate BAY 73-4506 mesylate	VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie	Cancer
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .

HY-10331S1

Regorafenib-13C,d3 BAY 73-4506-¹³C,d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-18652A

Avutometinib potassium Ro 5126766 potassium; CH5126766 potassium	Raf MEK	Cancer
Avutometinib (CH5126766) (potassium) is a *RAF/MEK* clamp that potently inhibits *RAF/MEK* kinase activity and induces dominant negative *RAF-MEK* complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .

HY-E70649

BRAF V600E Recombinant Human Active Protein Kinase	Raf	Cancer
BRAF is a member of the Raf kinase family of growth signal transduction protein kinases. BRAF has multiple mutants. BRAF V600E is commonly found in melanoma. BRAF V600E Recombinant Human Active Protein Kinase is a recombinant BRAF V600E protein that can be used to study BRAF V600E-related functions .

HY-E70746

MEK1 SESE Recombinant Human Active Protein Kinase	MEK	Cancer
MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 SESE is a mutant of MEK1. MEK1 SESE Recombinant Human Active Protein Kinase is a recombinant MEK1 SESE protein that can be used to study MEK1 SESE-related functions .

HY-10331R

Regorafenib (Standard) BAY 73-4506 (Standard)	Reference Standards VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331AR

Regorafenib monohydrate (Standard) BAY 73-4506 monohydrate (Standard)	Reference Standards VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-179098

*Multi-target kinase-IN-8*	Raf c-Met/HGFR Pim EGFR VEGFR Apoptosis	Cancer
Multi-target kinase-IN-8 (3d) is an anti-cancer agent. Multi-target kinase-IN-8 exhibits inhibitory activity against various protein kinases (B-Raf V600E (IC₅₀ = 0.078 µg/mL), c-Met (IC₅₀ = 0.405 µg/mL), Pim-1 (IC₅₀ = 1.053 µg/mL), EGFR WT (IC₅₀ = 0.177 µg/mL), VEGFR-2 (IC₅₀ = 0.275 µg/mL)). Multi-target kinase-IN-8 can induce cell cycle arrest and promote early and late apoptosis. Multi-target kinase-IN-8 is commonly used in cancer research .

HY-N3634

Corylifol C	EGFR TAM Receptor Tie	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-E70842

MAP2K1 L115P Recombinant Human Active Protein Kinase	MEK	Cancer
MAP2K1 (also known as MEK1) is downstream of the RAF family and activation results in ERK1/2 activation. Activating mutations in MAP2K1 have been reported almost exclusively in exons 1 and 2 in both hematologic malignancies. MAP2K1 L115P is a mutant of MAP2K1. MAP2K1 L115P Recombinant Human Active Protein Kinase is a recombinant MAP2K1 L115P protein that can be used to study MAP2K1 L115P-related functions .

HY-146303

*C-RAF* kinase-IN-1**	Raf	Cancer
C-RAF kinase-IN-1 (compound 1l) is a potent inhibitor of *C-RAF* kinase with an IC₅₀ of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .

HY-142452

*Pan-RAF* kinase inhibitor 1**	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .

HY-E70765

**RAF1 YDYD Recombinant Human Active Protein Kinase**	Raf	Cancer
Ras-associated factor -1 (RAF1) belongs to the RAF protein kinases family, also known as C-Raf. RAF1 participates in Ras-RAF-MEK-ERk signaling pathway (MAPK signaling pathway), and transmits extracellular signals into the nucleus through cell membrane receptors, thereby mediating the expression of intracellular specific proteins and participating in the regulation of cell proliferation, differentiation, apoptosis, autophagy and other functions. RAF1 YDYD is a mutant of RAF1. RAF1 YDYD Recombinant Human Active Protein Kinase is a recombinant RAF1 YDYD protein that can be used to study RAF1 YDYD-related functions .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

4,400 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 4,400 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Cat. No.	Product Name	Type

HY-10966G

SB-590885

Fluorescent Dyes

SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Cat. No.	Product Name	Type

HY-10966G

SB-590885

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1039A

R18 TFA PHCVPRDLSWLDLEANMCLP TFA	Raf	Cancer
R18 TFA is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Raf	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N15264

Azaspirene (-)-Azaspirene	Natural Products Microorganisms Source Classification	VEGFR Raf
Azaspirene ((-)-Azaspirene) is an angiogenesis and *Raf-1* activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and *Raf-1* activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .

Cat. No.	Product Name	Chemical Structure

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-12057S1

Vemurafenib-d7
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-12057S

Vemurafenib-d5
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10966G

SB-590885	Raf Apoptosis	Cardiovascular Disease Cancer
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a *BRAF/c-Raf* kinase inhibitor that selectively targets *B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf* cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Raf kinases

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products